Extrait

The main objective of the present trial is to find out whether mangafodipir, being a potent cardioprotective drug in animal studies, prevents reperfusion injury and reduces infarct size in patients during acute myocardial infarction.

Critère d'inclusion

• Patients with acute myocardial infarction decided for treatment by percutaneous coronary intervention (PCI) are included. The test drug mangafodipir is administered intravenously just prior to PCI. The objective is to prevent reperfusion injury on return of blood flow to the ischemic myocardium. If mangafodipir proves successful, the infarct size will be smaller, and the condition of the patient improved during the acute phase and thereafter

Liens

• ictrp
• euctr